Barely two weeks after the UK Patent Office granted an iPSC patent to Ipierian, a patent application by Rudolf Jaenisch of the Whitehead Institute,- entitled "Methods for Reprogramming Somatic Cells"-, has become the subject of a Notice of Allowance from the US Patent & Trademark Office.  According to a Press Release from Fate Therapeutics, Inc, "the patent will cover foundational induced pluripotent stem cell (iPSC) technology for identifying agents that enable the reprogramming of human somatic cells, including pluripotency genes, small molecules and biologics".  To view the Jaenisch patent application, click here.